Clinical Trial

A Study of IBR854 Combined With Pazopanib Versus Pazopanib in Advanced Renal Cell Carcinoma

Recruiting Phase 2
View on ClinicalTrials.gov →
Summary
This is a multicenter, randomized, open-label, active-controlled Phase II clinical study evaluating the efficacy and safety of IBR854 combined with Pazopanib versus Pazopanib in Advanced Renal Cell Carcinoma.
Protocol Amendment History 2 amendments
This ClinicalTrials.gov record has been amended 2 times since 2025-07-18; most recent amendment 2026-07-01.
Status change: Not Yet Recruiting → Recruiting 2026-07-01
Trial Details
NCT Number NCT07087158
Lead Sponsor Imbioray (Hangzhou) Biomedicine Co., Ltd.
Conditions Renal Cell Carcinoma (RCC)
Enrollment 30 participants
Start Date 2025-09-08
Primary Completion 2026-12-31 (estimated)
Study Completion 2026-12-31 (estimated)
Updated on ClinicalTrials.gov 2026-07-02